• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泛素特异性蛋白酶5(Usp5)将黑色素瘤中p53和FAS水平的抑制与BRAF信号通路联系起来。

Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.

作者信息

Potu Harish, Peterson Luke F, Pal Anupama, Verhaegen Monique, Cao Juxiang, Talpaz Moshe, Donato Nicholas J

机构信息

Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

Department of Dermatology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

出版信息

Oncotarget. 2014 Jul 30;5(14):5559-69. doi: 10.18632/oncotarget.2140.

DOI:10.18632/oncotarget.2140
PMID:24980819
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4170643/
Abstract

Usp5 is a deubiquitinase (DUB) previously shown to regulate unanchored poly-ubiquitin (Ub) chains, p53 transcriptional activity and double-strand DNA repair. In BRAF mutant melanoma cells, Usp5 activity was suppressed by BRAF inhibitor (vemurafenib) in sensitive but not in acquired or intrinsically resistant cells. Usp5 knockdown overcame acquired vemurafenib resistance and sensitized BRAF and NRAS mutant melanoma cells to apoptosis initiated by MEK inhibitor, cytokines or DNA-damaging agents. Knockdown and overexpression studies demonstrated that Usp5 regulates p53 (and p73) levels and alters cell growth and cell cycle distribution associated with p21 induction. Usp5 also regulates the intrinsic apoptotic pathway by modulating p53-dependent FAS expression. A small molecule DUB inhibitor (EOAI3402143) phenocopied the FAS induction and apoptotic sensitization of Usp5 knockdown and fully blocked melanoma tumor growth in mice. Overall, our results demonstrate that BRAF activates Usp5 to suppress cell cycle checkpoint control and apoptosis by blocking p53 and FAS induction; all of which can be restored by small molecule-mediated Usp5 inhibition. These results suggest that Usp5 inhibition can provide an alternate approach in recovery of diminished p53 (or p73) function in melanoma and can add to the targeted therapies already used in the treatment of melanoma.

摘要

Usp5是一种去泛素化酶(DUB),先前已证明它可调节未锚定的多聚泛素(Ub)链、p53转录活性和双链DNA修复。在BRAF突变的黑色素瘤细胞中,BRAF抑制剂(维莫非尼)可抑制敏感细胞中的Usp5活性,但对获得性耐药或固有耐药细胞无效。敲低Usp5可克服获得性维莫非尼耐药,并使BRAF和NRAS突变的黑色素瘤细胞对MEK抑制剂、细胞因子或DNA损伤剂引发的凋亡敏感。敲低和过表达研究表明,Usp5调节p53(和p73)水平,并改变与p21诱导相关的细胞生长和细胞周期分布。Usp5还通过调节p53依赖性FAS表达来调节内源性凋亡途径。一种小分子DUB抑制剂(EOAI3402143)模拟了Usp5敲低后的FAS诱导和凋亡致敏作用,并完全阻断了小鼠黑色素瘤肿瘤的生长。总体而言,我们的结果表明,BRAF通过阻断p53和FAS诱导来激活Usp5,从而抑制细胞周期检查点控制和凋亡;所有这些都可以通过小分子介导的Usp5抑制来恢复。这些结果表明,抑制Usp5可以为恢复黑色素瘤中p53(或p73)功能减弱提供另一种方法,并可补充已用于治疗黑色素瘤的靶向疗法。

相似文献

1
Usp5 links suppression of p53 and FAS levels in melanoma to the BRAF pathway.泛素特异性蛋白酶5(Usp5)将黑色素瘤中p53和FAS水平的抑制与BRAF信号通路联系起来。
Oncotarget. 2014 Jul 30;5(14):5559-69. doi: 10.18632/oncotarget.2140.
2
Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53.去泛素化酶USP5的抑制会导致游离多聚泛素的积累以及p53的激活。
J Biol Chem. 2009 Feb 20;284(8):5030-41. doi: 10.1074/jbc.M805871200. Epub 2008 Dec 19.
3
Tumor necrosis factor related apoptosis inducing ligand (TRAIL) regulates deubiquitinase USP5 in tumor cells.肿瘤坏死因子相关凋亡诱导配体(TRAIL)在肿瘤细胞中调节去泛素化酶USP5。
Oncotarget. 2019 Oct 8;10(56):5745-5754. doi: 10.18632/oncotarget.27196.
4
Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.通过使用ganetespib靶向抑制Hsp90克服黑色素瘤中获得性BRAF抑制剂耐药性。
Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.
5
ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.BRAF抑制剂治疗诱导产生的活性氧(ROS)重编程代谢过程,影响黑色素瘤细胞的生长。
Mol Cancer. 2017 Jun 8;16(1):102. doi: 10.1186/s12943-017-0667-y.
6
Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.新型小分子XPO1/CRM1抑制剂可诱导人黑色素瘤细胞中TP53的核聚集、磷酸化丝裂原活化蛋白激酶(MAPK)以及细胞凋亡。
PLoS One. 2014 Jul 24;9(7):e102983. doi: 10.1371/journal.pone.0102983. eCollection 2014.
7
Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.Mcl-1的过表达使黑色素瘤对BRAFV600E抑制剂单独使用以及与MEK1/2抑制剂联合使用均产生耐药性。
Oncotarget. 2015 Dec 1;6(38):40535-56. doi: 10.18632/oncotarget.5755.
8
CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma.CRM1 和 BRAF 抑制协同作用,诱导 BRAF 突变型黑色素瘤肿瘤消退。
Mol Cancer Ther. 2013 Jul;12(7):1171-9. doi: 10.1158/1535-7163.MCT-12-1171. Epub 2013 Apr 24.
9
The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression.新型ATP竞争性MEK/极光激酶抑制剂BI-847325通过抑制Mcl-1和MEK表达克服获得性BRAF抑制剂耐药性。
Mol Cancer Ther. 2015 Jun;14(6):1354-64. doi: 10.1158/1535-7163.MCT-14-0832. Epub 2015 Apr 14.
10
Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.蛋白激酶CK2α以一种不依赖CK2α激酶的方式维持细胞外信号调节激酶(ERK)活性,从而促进对BRAF突变型黑色素瘤中RAF和MEK抑制剂的耐药性,但对ERK抑制剂无耐药性。
J Biol Chem. 2016 Aug 19;291(34):17804-15. doi: 10.1074/jbc.M115.712885. Epub 2016 May 17.

引用本文的文献

1
Aberrant Notch-signaling promotes tumor angiogenesis in esophageal squamous-cell carcinoma.异常的Notch信号通路促进食管鳞状细胞癌的肿瘤血管生成。
Signal Transduct Target Ther. 2025 Jul 22;10(1):233. doi: 10.1038/s41392-025-02309-5.
2
DUBs in Alzheimer's disease: mechanisms and therapeutic implications.阿尔茨海默病中的去泛素化酶:机制及治疗意义
Cell Death Discov. 2024 Nov 20;10(1):475. doi: 10.1038/s41420-024-02237-3.
3
Unraveling the Mechanism of Action of Ubiquitin-Specific Protease 5 and Its Inhibitors in Tumors.解析泛素特异性蛋白酶5及其抑制剂在肿瘤中的作用机制

本文引用的文献

1
Ubiquitin-specific protease 5 is required for the efficient repair of DNA double-strand breaks.泛素特异性蛋白酶 5 对于 DNA 双链断裂的有效修复是必需的。
PLoS One. 2014 Jan 14;9(1):e84899. doi: 10.1371/journal.pone.0084899. eCollection 2014.
2
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.一种新型小分子去泛素化酶 USP14 和UCHL5 的抑制剂诱导多发性骨髓瘤细胞凋亡并克服硼替佐米耐药。
Blood. 2014 Jan 30;123(5):706-16. doi: 10.1182/blood-2013-05-500033. Epub 2013 Dec 6.
3
Reactivation of p53 as therapeutic intervention for malignant melanoma.
Clin Med Insights Oncol. 2024 Oct 9;18:11795549241281932. doi: 10.1177/11795549241281932. eCollection 2024.
4
The deubiquitinase USP9X regulates RIT1 protein abundance and oncogenic phenotypes.去泛素化酶USP9X调节RIT1蛋白丰度和致癌表型。
iScience. 2024 Jul 14;27(8):110499. doi: 10.1016/j.isci.2024.110499. eCollection 2024 Aug 16.
5
Unraveling the Immune Regulatory Functions of USP5: Implications for Disease Therapy.解析 USP5 的免疫调节功能:对疾病治疗的启示。
Biomolecules. 2024 Jun 12;14(6):683. doi: 10.3390/biom14060683.
6
Targeting Ubiquitin-specific Protease 5 Overcomes Chemoresistance via Negatively Regulating p53 in Gastric Cancer.靶向泛素特异性蛋白酶5通过负调控胃癌中的p53克服化疗耐药性。
Curr Mol Med. 2025;25(2):211-221. doi: 10.2174/0115665240278762240202103722.
7
Ubiquitin-specific protease 5 promotes bladder cancer progression through stabilizing Twist1.泛素特异性蛋白酶5通过稳定Twist1促进膀胱癌进展。
Oncogene. 2024 Mar;43(10):703-713. doi: 10.1038/s41388-023-02936-8. Epub 2024 Jan 13.
8
ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy.ERK 和 USP5 通过去泛素化来调节 PD-1 稳态,从而调节肿瘤免疫治疗。
Nat Commun. 2023 May 19;14(1):2859. doi: 10.1038/s41467-023-38605-3.
9
Protein degradation: expanding the toolbox to restrain cancer drug resistance.蛋白质降解:扩展工具箱以抑制癌症耐药性。
J Hematol Oncol. 2023 Jan 24;16(1):6. doi: 10.1186/s13045-023-01398-5.
10
p53 Family in Resistance to Targeted Therapy of Melanoma.p53 家族在抵抗黑色素瘤的靶向治疗中的作用。
Int J Mol Sci. 2022 Dec 21;24(1):65. doi: 10.3390/ijms24010065.
p53 的再激活作为治疗恶性黑色素瘤的干预手段。
Curr Opin Oncol. 2014 Jan;26(1):114-9. doi: 10.1097/CCO.0000000000000033.
4
Tumor adaptation and resistance to RAF inhibitors.肿瘤的适应性和对 RAF 抑制剂的耐药性。
Nat Med. 2013 Nov;19(11):1401-9. doi: 10.1038/nm.3392.
5
Deubiquitylases from genes to organism.从基因到生物体的去泛素化酶。
Physiol Rev. 2013 Jul;93(3):1289-315. doi: 10.1152/physrev.00002.2013.
6
Reading, writing, and repair: the role of ubiquitin and the ubiquitin-like proteins in DNA damage signaling and repair.阅读、书写和修复:泛素和泛素样蛋白在 DNA 损伤信号转导和修复中的作用。
Front Genet. 2013 Apr 1;4:45. doi: 10.3389/fgene.2013.00045. eCollection 2013.
7
mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6.mTOR 通过控制 ULK1 的泛素化、自聚集和功能,通过 AMBRA1 和 TRAF6 来抑制自噬。
Nat Cell Biol. 2013 Apr;15(4):406-16. doi: 10.1038/ncb2708. Epub 2013 Mar 24.
8
Dual coordination of post translational modifications in human protein networks.人类蛋白质网络中翻译后修饰的双重协调
PLoS Comput Biol. 2013;9(3):e1002933. doi: 10.1371/journal.pcbi.1002933. Epub 2013 Mar 7.
9
Ubiquitylation-dependent localization of PLK1 in mitosis.泛素化依赖性的 PLK1 在有丝分裂中的定位。
Nat Cell Biol. 2013 Apr;15(4):430-9. doi: 10.1038/ncb2695. Epub 2013 Mar 3.
10
The Akt DUBbed InAktive.Akt 双泛素化失活酶。
Sci Signal. 2013 Jan 8;6(257):pe1. doi: 10.1126/scisignal.2003864.